Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (15)

2021

  1. Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: Results from a multicenter region-wide cohort study (2014-2018)

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 2, pp. 279-287

  2. Self-rated health among people living with HIV in Spain in 2019: a cross-sectional study

    BMC Infectious Diseases, Vol. 21, Núm. 1

2020

  1. Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?

    AIDS, Vol. 34, Núm. 3, pp. 427-432

  2. Results of the implantation of a protocol for correction of preoperative anemia in the intensified recovery of elective colorectal surgery

    Revista de Cirugia, Vol. 72, Núm. 1, pp. 48-58

  3. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Implementation of an Enhanced Recovery After Surgery program in elective colorectal surgery: a prospective cohort study

    Journal of Coloproctology, Vol. 39, Núm. 3, pp. 249-257

2018

  1. C-reactive protein as a marker of the surgical stress reduction within an ERAS protocol (Enhanced Recovery After Surgery) in colorectal surgery: A prospective cohort study

    Journal of Surgical Oncology, Vol. 117, Núm. 4, pp. 717-724

  2. C-reactive protein as a marker of the systemic inflammatory response to surgery reduction within an enhanced recovery after surgery protocol in elective colorectal surgery of the elderly: A prospective cohort study

    Surgical Practice, Vol. 22, Núm. 3, pp. 116-124

  3. Satisfaction survey after an ERAS (Enhanced Recovery after Surgery) protocol in colorectal elective surgery in patients over 70 years of age

    Colombian Journal of Anesthesiology, Vol. 46, Núm. 3, pp. 187-195

2004

  1. Clinical, Virologic, and Immunologic Response to Efavirenz- or Protease Inhibitor-Based Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients with Advanced HIV Infection (EfaVIP 2 Study)

    Journal of Acquired Immune Deficiency Syndromes, Vol. 35, Núm. 4, pp. 343-350

2002

  1. Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por el virus de la inmunodeficiencia humana en España

    Medicina Clinica, Vol. 119, Núm. 19, pp. 721-724

  2. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: The Efa VIP study (Efavirenz in very immunosuppressed patients)

    AIDS, Vol. 16, Núm. 11, pp. 1554-1556

  3. Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy [3]

    AIDS

  4. NNRTI hepatotoxicity: efavirenz versus nevirapine.

    Journal of HIV therapy, Vol. 7 Suppl 2

2001

  1. Efficacy and toxicity of treatment with efavirenz or indinavir plus zidovudine and lamivudine: An approach according to evidence-based medicine

    Enfermedades Emergentes, Vol. 3, Núm. 1, pp. 28-32